COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies

During the visit carried out as part of the follow-up, participation in this study will be proposed to any patient who is treated for a malignant disease (solid or hematological tumors) within the university hospitals of AP-HP.Nord. The patients participating in this prospective cohort will benefit from all standard care his/her condition requires. Clinical and biological data will be collected as part of the usual follow-up. Clinical data: pathology, stage, treatment line, type of current treatment and date of the last treatment administered, previous treatments, radiotherapy, concept of radiation lung disease, history of pneumonectomy, comorbidities, performance status, history of coronavirus disease 2019 (COVID-19). Laboratory data: pre-vaccination polynuclear neutrophil count, lymphocyte counts, plasma protein electrophoresis or Ig weight dosage (routine care in hematology), lactate dehydrogenase (LDH), C-reactive protein (CRP), albuminemia in the previous month. Vaccination data: type of vaccine, date of the 1st injection, date of the 2nd injection, pre-vaccination antibody levels * Seroconversion with anti-S IgG after anti-Sars-CoV-2 vaccination * Anti-S and / or anti-N Sars-CoV-2 IgG seroprevalence before vaccination * Adverse effects related to vaccines * Levels of the anti-S IgG antibodies in AU / ml During visits between D21 and D28 (before the 2nd injection), at month 3, month 6 and month 12, the following data will be collected: * Antibody levels * Adverse effects related to vaccines * Levels of the anti-S IgG antibodies in AU / ml * Associated side effects * Occurrence of COVID-19.